Predictors of Adherence to Orencia | NCT01136707 | Trialant
CompletedObservationalUpdated Sep 16, 2016
Predictors of Adherence to Orencia
Predictors of Adherence to Orencia
ClinicalTrials.gov ID
NCT01136707
Lead Sponsor
Bristol-Myers SquibbINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
422Actual
Last Update Posted
Sep 16, 2016Estimated
Start Date
Dec 2009
Primary Completion Date
Jul 2010Actual
Completion Date
Jul 2010Actual
Official Title
Predictors of Adherence to Orencia
Brief Summary
The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.
Rheumatoid Arthritis
No interventions
There are no interventions for this study.
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients will be identified based on the presence of first infusion claim during study period for Orencia
At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date
Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below
Patients with a minimum of 3 infusion claims for Orencia
Only those patients will be included whose first 3 infusion claims occur within 84 days
Exclusion Criteria:
Patients less than 18 years of age at index date.
One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period
Patients who switch between biologics within their first three infusion claims
Restarts, defined as those patients who go back on Orencia after a gap of 42 days
Patients who are on other biologics at the same time as Orencia